Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 7.77
(1.17%)
SEK 7.77
(1.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -3.42 Million SEK | 5.29% |
| 2022 | -3.61 Million SEK | -0.39% |
| 2021 | -3.59 Million SEK | -1.72% |
| 2020 | -3.53 Million SEK | -164.35% |
| 2019 | -1.33 Million SEK | 93.7% |
| 2018 | -21.24 Million SEK | -694.02% |
| 2017 | 3.57 Million SEK | 72.55% |
| 2016 | 2.07 Million SEK | 25.18% |
| 2015 | 1.65 Million SEK | -27.72% |
| 2014 | 2.29 Million SEK | -43.08% |
| 2013 | 4.02 Million SEK | 1187215.63% |
| 2012 | 339.00 SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 104.24 Million SEK | 302.83% |
| 2024 Q2 | -839 Thousand SEK | -100.8% |
| 2023 Q4 | -51.39 Million SEK | -6018.33% |
| 2023 Q1 | -903 Thousand SEK | 0.0% |
| 2023 Q2 | -839 Thousand SEK | 7.09% |
| 2023 FY | -3.42 Million SEK | 5.29% |
| 2023 Q3 | -840 Thousand SEK | -0.12% |
| 2022 Q1 | -903 Thousand SEK | 0.0% |
| 2022 Q2 | -903 Thousand SEK | 0.0% |
| 2022 FY | -3.61 Million SEK | -0.39% |
| 2022 Q3 | -903 Thousand SEK | 0.0% |
| 2022 Q4 | -903 Thousand SEK | 0.0% |
| 2021 Q1 | -909 Thousand SEK | 0.0% |
| 2021 Q4 | -903 Thousand SEK | 0.0% |
| 2021 Q3 | -903 Thousand SEK | -2.27% |
| 2021 Q2 | -883 Thousand SEK | 2.86% |
| 2021 FY | -3.59 Million SEK | -1.72% |
| 2020 FY | -3.53 Million SEK | -164.35% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 FY | -1.33 Million SEK | 93.7% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 100.0% |
| 2018 Q4 | -6.11 Million SEK | -879.49% |
| 2018 Q3 | 785 Thousand SEK | -4.73% |
| 2018 Q1 | 843 Thousand SEK | -10.7% |
| 2018 FY | -21.24 Million SEK | -694.02% |
| 2018 Q2 | 824 Thousand SEK | -2.25% |
| 2017 FY | 3.57 Million SEK | 72.55% |
| 2017 Q4 | 944 Thousand SEK | 4.54% |
| 2017 Q3 | 903 Thousand SEK | 10.53% |
| 2017 Q2 | 817 Thousand SEK | -10.51% |
| 2017 Q1 | 913 Thousand SEK | 13.28% |
| 2016 Q1 | 427 Thousand SEK | -10.86% |
| 2016 FY | 2.07 Million SEK | 25.18% |
| 2016 Q3 | 380 Thousand SEK | -17.39% |
| 2016 Q2 | 460 Thousand SEK | 7.73% |
| 2016 Q4 | 806 Thousand SEK | 112.11% |
| 2015 Q1 | 337 Thousand SEK | 137.03% |
| 2015 FY | 1.65 Million SEK | -27.72% |
| 2015 Q2 | 364 Thousand SEK | 8.01% |
| 2015 Q4 | 479 Thousand SEK | 0.63% |
| 2015 Q3 | 476 Thousand SEK | 30.77% |
| 2014 Q4 | -910 Thousand SEK | -983.33% |
| 2014 Q3 | -84 Thousand SEK | 88.63% |
| 2014 FY | 2.29 Million SEK | -43.08% |
| 2014 Q2 | -738.5 Thousand SEK | 0.0% |
| 2014 Q1 | -738.5 Thousand SEK | -1267.59% |
| 2013 Q1 | -568.50 SEK | -53.65% |
| 2013 Q3 | 35 Thousand SEK | 106.16% |
| 2013 Q4 | -54 Thousand SEK | -254.29% |
| 2013 FY | 4.02 Million SEK | 1187215.63% |
| 2013 Q2 | -568.5 Thousand SEK | -99900.0% |
| 2012 Q3 | 143.00 SEK | 0.0% |
| 2012 Q4 | -370.00 SEK | -358.74% |
| 2012 FY | 339.00 SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 97.871% |
| Ziccum AB (publ) | -23.28 Million SEK | 85.309% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.988% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 108.187% |
| Mendus AB (publ) | 28.48 Million SEK | 112.009% |
| Genovis AB (publ.) | 54 Million SEK | 106.335% |
| Intervacc AB (publ) | -13.79 Million SEK | 75.199% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 257.577% |
| Active Biotech AB (publ) | -1.67 Million SEK | -104.239% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 134.337% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 112.755% |
| Aptahem AB (publ) | 2.63 Million SEK | 230.044% |
| Kancera AB (publ) | -1.96 Million SEK | -74.097% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 4542.857% |
| Fluicell AB (publ) | 1.73 Million SEK | 296.835% |
| Saniona AB (publ) | 11.78 Million SEK | 129.038% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 33.144% |
| Biovica International AB (publ) | 6.87 Million SEK | 149.746% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 85.307% |
| AcouSort AB (publ) | 8.38 Million SEK | 140.78% |
| Xintela AB (publ) | 78 Thousand SEK | 4485.897% |
| Abliva AB (publ) | -35.66 Million SEK | 90.407% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 97.671% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 221.874% |
| OncoZenge AB (publ) | 3000.00 SEK | 114133.333% |
| Amniotics AB (publ) | -1.93 Million SEK | -77.254% |
| 2cureX AB (publ) | -37.48 Million SEK | 90.874% |
| CombiGene AB (publ) | -21.29 Million SEK | 83.932% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -708.747% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.303% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.216% |
| Corline Biomedical AB | 28.38 Million SEK | 112.054% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 97.213% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 90.06% |
| I-Tech AB | 27.56 Million SEK | 112.41% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 104.822% |
| Cyxone AB (publ) | 2.61 Million SEK | 231.023% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 200.529% |
| Biosergen AB | -456 Thousand SEK | -650.219% |
| Cantargia AB (publ) | -3.45 Million SEK | 0.869% |
| NextCell Pharma AB | -43.74 Million SEK | 92.18% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 62.791% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 130.495% |
| Nanologica AB (publ) | -76 Thousand SEK | -4401.316% |
| SynAct Pharma AB | -778 Thousand SEK | -339.717% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -1672.539% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 73.526% |
| Lipum AB (publ) | 53 Thousand SEK | 6554.717% |
| BioInvent International AB (publ) | 71.46 Million SEK | 104.787% |
| Alzinova AB (publ) | 19.87 Million SEK | 117.213% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 109.425% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 333.831% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -22706.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 306.333% |
| Simris Alg AB (publ) | 2 Million SEK | 270.453% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 4.441% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 109.667% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -226.12% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 209.192% |